Form 4: ImmunityBio Director Linda Maxwell Granted Over 162,000 Stock Options

ImmunityBio, Inc. Director Linda Maxwell was granted 162,786 stock options with an exercise price of $2.84, vesting on the earlier of June 18, 2026, or the next annual meeting.

Summary

• ImmunityBio, Inc. (IBRX) Director Linda Maxwell was granted 162,786 stock options.
• The options have an exercise price of $2.84 per share.
• The transaction date for this grant was June 18, 2025.
• The options are subject to a vesting schedule where 100% of the shares will vest on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Ms. Maxwell's continued service as a Service Provider, as defined in the Issuer's 2025 Equity Incentive Plan.
• The expiration date for these stock options is June 18, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of stock options to a director is a routine compensation event that aligns management interests with shareholders, which is generally viewed favorably. There are no negative implications or significant risks disclosed in this specific filing.

Positives

• The grant of stock options to Director Linda Maxwell aligns her financial interests with those of the company's shareholders, incentivizing long-term performance and value creation.
• The options are granted under the Issuer's 2025 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Risks

• The vesting of the stock options is subject to Linda Maxwell's continuing to be a Service Provider, meaning the options could be forfeited if her service terminates before the vesting date.

Future Outlook

The grant of stock options indicates a future potential increase in Linda Maxwell's beneficial ownership of ImmunityBio common stock, contingent upon the options vesting and being exercised. The vesting schedule provides a clear timeline for when these options could convert into shares.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize board members. This type of equity compensation aligns the director's long-term interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a common practice across publicly traded companies, including those in the biotechnology sector like ImmunityBio.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization, stage of development, and industry, though this document does not provide such comparative data.
• The vesting schedule, tied to continued service and a specific future date or corporate event (annual meeting), is a standard mechanism to ensure retention and long-term commitment, consistent with corporate governance best practices.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: While not directly impacting employees, the equity incentive plan framework may also apply to other service providers, potentially influencing broader compensation strategies.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the date immediately preceding ImmunityBio's next annual meeting of stockholders, provided Linda Maxwell continues her service.

Key Dates

Keywords

ImmunityBio, IBRX, SEC Form 4, Stock Option, Director Compensation, Equity Incentive Plan, Insider Transaction, Linda Maxwell